Skip to content

9 Meters Biopharma, Inc.: 10-Q filed 2016-08-15

What 9 Meters Biopharma, Inc. reported in its quarterly report filed 2016-08-15 (fiscal Q2 2016): 29 published measures, 75 facts as tagged in accession 0001144204-16-118917.

This filing

Form
10-Q (quarterly report)
Filed
2016-08-15
Fiscal period
fiscal Q2 2016
Accession
0001144204-16-118917 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All 9 Meters Biopharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-06-305,924,000USD
At 2015-12-314,718,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-06-30-6,243,000USD
At 2015-12-31-5,694,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-1,240,000USD91
2016-01-01 to 2016-06-30-3,121,000USD182
2015-04-01 to 2015-06-30-1,156,000USD91
2015-01-01 to 2015-06-30-4,277,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-06-30-28,996,000USD
At 2015-12-31-25,875,000USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-04-01 to 2016-06-300USD91
2016-01-01 to 2016-06-300USD182
2015-04-01 to 2015-06-300USD91
2015-01-01 to 2015-06-300USD181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-06-30179,000USD182
2015-01-01 to 2015-06-3054,000USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-901,000USD91
2016-01-01 to 2016-06-30-2,334,000USD182
2015-04-01 to 2015-06-30-1,057,000USD91
2015-01-01 to 2015-06-30-2,749,000USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-06-302,273,000USD
At 2015-12-311,537,000USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-06-30339,000USD91
2016-01-01 to 2016-06-30787,000USD182
2015-04-01 to 2015-06-3099,000USD91
2015-01-01 to 2015-06-30630,000USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-06-3012,167,000USD
At 2015-12-3110,412,000USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-06-301,466,000USD
At 2015-12-311,021,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2016-06-302,483,000USD
At 2015-12-312,548,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-06-301,038,000USD
At 2015-12-31644,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,331,000USD91
2016-01-01 to 2016-06-302,811,000USD182
2015-04-01 to 2015-06-301,143,000USD91
2015-01-01 to 2015-06-303,010,000USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2016-06-301,029,000USD
At 2015-12-31633,000USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2016-04-01 to 2016-06-30430,000USD91
2016-01-01 to 2016-06-30477,000USD182
2015-04-01 to 2015-06-3086,000USD91
2015-01-01 to 2015-06-30261,000USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-04-01 to 2016-06-3065,000USD91
2016-01-01 to 2016-06-30114,000USD182
2015-04-01 to 2015-06-30119,000USD91
2015-01-01 to 2015-06-30246,000USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-06-303,750,000shares
At 2015-12-313,702,865shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-06-3022,753,000USD
At 2015-12-3120,181,000USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2016-06-3029,000,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2016-06-303,628,000USD
At 2015-12-313,311,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-06-3054,000USD
At 2015-12-31141,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-1,240,000USD91
2016-01-01 to 2016-06-30-3,121,000USD182
2015-04-01 to 2015-06-30-1,156,000USD91
2015-01-01 to 2015-06-30-4,277,000USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30675,000USD91
2016-01-01 to 2016-06-301,470,000USD182
2015-04-01 to 2015-06-30492,000USD91
2015-01-01 to 2015-06-301,375,000USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2016-01-01 to 2016-06-3065,000USD182
2015-01-01 to 2015-06-300USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2016-01-01 to 2016-06-3029,000USD182
2015-01-01 to 2015-06-30142,000USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-30513,000USD182
2015-01-01 to 2015-06-30-2,998,000USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-30396,000USD182
2015-01-01 to 2015-06-301,202,000USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-30445,000USD182
2015-01-01 to 2015-06-301,453,000USD181

Inspect the source

Entity
9 Meters Biopharma, Inc. / CIK 0001551986
Captured
SEC response SHA-256
59d642aec339d0632a0e624932e840a466f1b38d6bf6e39062c538e5ae599884

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001551986.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))